Centre Jean Perrin — Clinical Trial Site

195 Registered trials

98 Currently recruiting

Organisation

Centre Jean Perrin

Location

Clermont-Ferrand, France

Identifier

ORG-100010125

Address

58 Rue Montalembert, 63011, France

Departments

#1001: Medical Oncology
#1202: Oncologie
#2157: Oncology
033022: Oncologie Medicale - Cancerolo
03311: Service d' Oncologie Médicale
1204: Oncologie
1504:Medical Oncology
2000: Medical oncology
2152: Oncologie
2304 Oncology Medical
2314:Medecine
3099:Oncology
Cancérologie
Cardiology/EP
Chirurgie
Chirurgie gynécologique
Chirurgie Oncologique
Critical Care Medicine
Département d'oncologie
Département d'oncologie médicale
Département de Médecine
Department of Medical Oncology
Department of Oncology
Department of Urology
digestive oncology
Gynecological surgery
Internal Medicine
Médecine interne
Medecine nucleaire
Médecine Nucléaire/ Hépato-Gastro-Entérologie
medecine nuclear department
Médecine oncologique
Medical ICU
Medical Oncology
Medical Oncology Department
N/A
NA
Neurologie
NEUROLOGY
Nuclear Medicine
Oncologie
Oncologie digestive
Oncologie Médicale
Oncologie thoracique et sarcome
Oncologue
Oncology
Oncology & Clin. Research
Oncology & Clinical Research
Oncology clinic
Oncology Department
Oncology for adults
Radiation oncology
Radiothérapie
Radiotherapy
Radiotherapy for adults
Radiotherapy Oncology
Réanimation/USC
Service d Oncologie
Service D Oncologie Medicale
Service d'Oncologie
Service d'Oncologie Médicale
Service d’Anesthésie et Réanimation
Service d’oncologie
Service de Médecine Intensive Réanimation
Service oncologie
Service Oncologie Medicale
Urologie

Clinical trials at this site (195)

Search interface

Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended

2023-510390-33-00 HER2-negative breast cancer patients with high relapse 5 2020-10-23
An open study for participants who have been on darolutamide treatment in any other Bayer study Ended

2022-502084-38-00 Cancer 5 2020-10-16
A Phase 1, Open-Label, Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in… Ended

2024-518506-41-00 metastatic castrate resistant prostate cancer 9 2020-10-05
Study of Cabozantinib in Combination With Atezolizumab compared to Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castratio… Ended

2024-516481-11-00 Metastatic Castration-Resistant Prostate Cancer 5 2020-09-22
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Palbociclib and Fulvestrant versus Placebo Plus Palbociclib and Fulvestrant in… Ended

2023-505812-39-00 HR+/HER2-Negative Locally Advanced or Metastatic Breast 5 2020-08-28
Efficacy and Safety of L19TNF in Previously Treated Patients With Advanced Stage or Metastatic Soft-tissue Sarcoma Ended

2024-512704-20-00 Unresectable and/or metastatic soft-tissue sarcoma afte 4 2020-06-22
Study comparing two standard treatments as initial metastatic treatment among patients with visceral metastasis of ER+ HER2- breast cancer, … Ended

2024-513005-31-00 Patients with untreated metastatic Estrogen Receptor po 5 2020-06-11
A Phase 3 Trial Comparing Selpercatinib to Cabozantinib or Vandetanib in Patients with RET-Mutant Medullary Thyroid Cancer Ended

2023-506782-56-00 RET-Mutant Medullary Thyroid Cancer 5 2020-03-10
Study assessing the efficacy and safety of durvalumab plus olaparib plus fulvestrant in selected metastatic or locally advanced ER-positive,… Ended

2024-516847-23-00 ER-positive and HER2-negative metastatic or locally adv 4 2019-08-27
A Phase II study of post-operative palbociclib as an alternative to chemotherapy in older patients with localized breast cancer at high risk… Ended

2023-505223-31-00 Localized ER+ breast cancer 4 2019-06-14
Phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer considering two different… Ended

2024-514706-31-01 Epithelial ovarian cancer, Fallopian tube ovarian cance 5 2019-05-02
Phase III study of pembrolizumab for high-risk early-stage ER+/HER2– breast cancer Ended

2023-506921-12-00 ER+/HER2- Breast Cancer 5 2018-12-27
The FIRST (First-line ovarian cancer treatment with Niraparib plus TSR-042) Study Ended

2024-510605-28-00 Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer 5 2018-11-27
Immunotherapy with ipilimumab and nivolumab preceded or not by a targeted therapy with encorafenib and binimetinib Ended

2023-505376-30-00 BRAF V600 mutation–positive unresectable or metastatic 4 2018-10-30
Randomized trial evaluating the addition of nivolumab to cisplatin-radiotherapy combination for treatment of cancers of the head and neck Ended

2024-513206-65-00 resected squamous cell carcinoma of head and neck 5 2018-08-10
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (COMPETE) Ended

2023-510444-21-00 Neuroendocrine tumours of gastroenteric or pancreatic o 5 2017-11-24
Randomized trial of avelumab-cetuximab-Radiotherapy versus standards of care in the head and neck cancers Ended

2024-513964-24-00 Squamous cell carcinoma, previously untreated Stage III 5 2017-09-14
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) Ended

2023-509671-17-00 Breast Cancer 5 2017-07-12
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection Ended

2024-510704-37-00 ER+/HER2- metastatic breast cancer 5 2017-03-22
CheckMate 274 Ended

2022-500630-29-00 Subjects with High Risk Invasive Urothelial Carcinoma 5 2016-05-06
RANDOMIZED STUDY COMPARING SENTINEL NODE POLICY TO CURRENT INITIAL STAGING PROTOCOLS IN EARLY STAGE ENDOMETRIAL CARCINOMAS AT INTERMEDIATE A… Ended

2024-513079-42-00 Intermediate-risk, high risk endometrial cancer 5 2015-11-19
Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended

2024-511096-15-00 Breast Cancer 5 2014-08-01
A Clinical study to assess the safety and effectiveness of ARN-509 in men with Castration-Resistant Prostate Cancer (prostate cancer not res… Ended

2023-509221-47-00 Castration-Resistant Prostate Cancer 5 2014-02-12
A large-scale comparative study evaluating an intravenous treatment, cabazitaxel, and radiation therapy to the pelvic lymph nodes in patient… Ended

2024-517622-25-00 Patients with localized prostate cancer and high-risk f 5 2013-12-06